Director, Business Development Division
Samuel joined UBP in 2014. He has more than 14 years of experience in biological drug development. His background includes extensive experience with preclinical in vitro pharmacology studies and animal studies for pharmacokinetics/pharmacodynamics/toxicology, as well as bioanalytical method development and validation.
He has cooperated with many global and local contract research organizations (CROs) including Charlies River Laboratories, Covance, Joinn laboratories, etc. His experiences include CRO evaluation, preclinical animal study design, cost estimation, project management, analytical method transfer, site audit, and pre-IND consultation. He also completed many IND submissions to US FDA, China NMPA, and Taiwan FDA.
In Fountain Biopharma (now merged into Oneness Biotech), he was responsible for the preclinical CRO work of FB825 and participated in the FDA IND submission. This project is currently the largest out-licensing deal for new biological drugs in Taiwan.
He received a master's degree in microbiology and immunology from National Cheng Kung University, Taiwan.